HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest
- PMID: 17283158
- DOI: 10.1158/0008-5472.CAN-06-3377
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest
Abstract
HIV protease inhibitors (HIV PI) are a class of antiretroviral drugs that are designed to target the viral protease. Unexpectedly, this class of drugs is also reported to have antitumor activity. In this study, we have evaluated the in vitro activity of nelfinavir, a HIV PI, against human melanoma cells. Nelfinavir inhibits the growth of melanoma cell lines at low micromolar concentrations that are clinically attainable. Nelfinavir promotes apoptosis and arrests cell cycle at G(1) phase. Cell cycle arrest is attributed to inhibition of cyclin-dependent kinase 2 (CDK2) and concomitant dephosphorylation of retinoblastoma tumor suppressor. We further show that nelfinavir inhibits CDK2 through proteasome-dependent degradation of Cdc25A phosphatase. Our results suggest that nelfinavir is a promising candidate chemotherapeutic agent for advanced melanoma, for which novel and effective therapies are urgently needed.
Similar articles
-
Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.Anticancer Drugs. 2006 Sep;17(8):891-903. doi: 10.1097/01.cad.0000224448.08706.76. Anticancer Drugs. 2006. PMID: 16940799
-
HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.Cancer Res. 2005 Sep 15;65(18):8256-65. doi: 10.1158/0008-5472.CAN-05-1220. Cancer Res. 2005. PMID: 16166302
-
Discovery and evaluation of dual CDK1 and CDK2 inhibitors.Cancer Res. 2006 Apr 15;66(8):4299-308. doi: 10.1158/0008-5472.CAN-05-2507. Cancer Res. 2006. PMID: 16618755
-
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.Curr Opin Oncol. 2013 Sep;25(5):495-502. doi: 10.1097/CCO.0b013e328363dfee. Curr Opin Oncol. 2013. PMID: 23872785 Free PMC article. Review.
-
The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir.Cancers (Basel). 2020 Nov 19;12(11):3437. doi: 10.3390/cancers12113437. Cancers (Basel). 2020. PMID: 33228205 Free PMC article. Review.
Cited by
-
Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by Proteasome Inhibition.Cancers (Basel). 2021 Dec 26;14(1):99. doi: 10.3390/cancers14010099. Cancers (Basel). 2021. PMID: 35008264 Free PMC article.
-
Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer.Sci Rep. 2015 Apr 16;5:9698. doi: 10.1038/srep09698. Sci Rep. 2015. PMID: 25880275 Free PMC article.
-
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?AIDS. 2016 Jun 19;30(10):1629-37. doi: 10.1097/QAD.0000000000001053. AIDS. 2016. PMID: 26854812 Free PMC article.
-
Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.Ther Clin Risk Manag. 2015 May 18;11:807-19. doi: 10.2147/TCRM.S82049. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 26056460 Free PMC article. Review.
-
The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.Onco Targets Ther. 2017 May 16;10:2581-2593. doi: 10.2147/OTT.S136484. eCollection 2017. Onco Targets Ther. 2017. PMID: 28553123 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous